{"id":"W2965089489","doi":"10.1016/s1470-2045(19)30171-8","title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"European Research Council; Weill Cornell Medical College; Genentech; Labex Immuno-Oncology; European Research Area Network on Cardiovascular Diseases; PharmaMar; Institut Universitaire de France; Chancellerie des Universités de Paris; Cancéropôle Ile de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Fondation pour la recherche juridique; U.S. Department of Defense; European Commission; Institut National de la Santé et de la Recherche Médicale; Bayer HealthCare; Servier; AstraZeneca; Institut National Du Cancer; Fondation Leducq; Agence Nationale de la Recherche; E-Rare; Bristol-Myers Squibb; Direction Générale de l’offre de Soins; Association pour la Recherche sur le Cancer; Seerave Foundation","keywords":"Radioimmunotherapy; Immunotherapy; Medicine; Radiation therapy; Toxicity; Oncology; Internal medicine; Cancer; Immunology; Monoclonal antibody; Antibody","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001241575,0.0002984938,0.003153604,0.0001234724,0.00006569167,0.00001466025,0.0002640658,0.000361519,0.0001687874],"category_scores_gemma":[0.00006445673,0.0001740769,0.0003301578,0.0002908142,0.0004066157,0.00002733748,0.00006878718,0.0005480699,0.000009231953],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002878789,"about_ca_system_score_gemma":0.000694608,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005743261,"about_ca_topic_score_gemma":0.000002635877,"domain_scores_codex":[0.998164,0.0003356599,0.0006373544,0.0003348841,0.0001833583,0.0003447608],"domain_scores_gemma":[0.9978686,0.0007207083,0.0005688887,0.0007495537,0.00004903933,0.00004319155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00130255,0.00008249911,0.000006192572,0.007766603,0.0008284284,0.00000811045,0.0002686012,8.90108e-7,0.0004673424,0.0000499554,0.001120994,0.9880978],"study_design_scores_gemma":[0.003429644,0.0007429316,0.0001095967,0.009243932,0.001120623,0.0004063326,0.00002010213,0.000007220795,0.00005700501,0.000006833265,0.9846777,0.0001780778],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001353458,0.9934805,0.00001917669,0.0007974821,0.0005298209,0.001174391,0.0000199254,0.00003142631,0.002593791],"genre_scores_gemma":[0.0001895899,0.997278,0.0006664989,0.0006551443,0.0006693744,0.00002730142,0.00001737406,0.00004998723,0.0004467024],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9879197,"threshold_uncertainty_score":0.7098652,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1501223898713991,"score_gpt":0.4359337749444891,"score_spread":0.28581138507309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}